CL2018001172A1 - CD80 extracellular domain polypeptides and their use in cancer treatment - Google Patents
CD80 extracellular domain polypeptides and their use in cancer treatmentInfo
- Publication number
- CL2018001172A1 CL2018001172A1 CL2018001172A CL2018001172A CL2018001172A1 CL 2018001172 A1 CL2018001172 A1 CL 2018001172A1 CL 2018001172 A CL2018001172 A CL 2018001172A CL 2018001172 A CL2018001172 A CL 2018001172A CL 2018001172 A1 CL2018001172 A1 CL 2018001172A1
- Authority
- CL
- Chile
- Prior art keywords
- extracellular domain
- cancer treatment
- domain polypeptides
- ecd
- agents
- Prior art date
Links
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 title abstract 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
LA PRESENTE SOLICITUD HACE REFERENCIA A POLIPÉPTIDOS DEL DOMINIO EXTRACELULAR (ECD) DE LA CD80 (B7-1) Y MOLÉCULAS DE FUSIÓN AL ECD DE LA CD80 Y SU USO EN EL TRATAMIENTO DEL CÁNCER, TANTO SOLOS COMO EN COMBINACIÓN CON OTROS AGENTES TERAPÉUTICOS, TALES COMO AGENTES QUE ESTIMULAN EL SISTEMA INMUNITARIO TALES COMO INHIBIDORES DE PD-1/PD-L1.THIS APPLICATION REFERENCES TO POLYPEPTIDES OF THE EXTRACELLULAR DOMAIN (ECD) OF THE CD80 (B7-1) AND FUSION MOLECULES TO THE ECD OF THE CD80 AND ITS USE IN THE TREATMENT OF CANCER, BOTH ONLY AS IN COMBINATION WITH OTHER THERAPE AGENTS AS AGENTS THAT STIMULATE THE IMMUNITY SYSTEM AS SUCH INHIBITORS OF PD-1 / PD-L1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562249836P | 2015-11-02 | 2015-11-02 | |
US201662373654P | 2016-08-11 | 2016-08-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018001172A1 true CL2018001172A1 (en) | 2018-09-21 |
Family
ID=57286882
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018001172A CL2018001172A1 (en) | 2015-11-02 | 2018-05-02 | CD80 extracellular domain polypeptides and their use in cancer treatment |
CL2020003392A CL2020003392A1 (en) | 2015-11-02 | 2020-12-28 | CD80 Extracellular Domain Polypeptides and Their Use in Cancer Treatment (Divisional Application No. 201801172) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020003392A CL2020003392A1 (en) | 2015-11-02 | 2020-12-28 | CD80 Extracellular Domain Polypeptides and Their Use in Cancer Treatment (Divisional Application No. 201801172) |
Country Status (21)
Country | Link |
---|---|
US (4) | US10273281B2 (en) |
EP (1) | EP3371208A1 (en) |
JP (1) | JP6936221B2 (en) |
KR (1) | KR20180069903A (en) |
CN (1) | CN108884139A (en) |
AU (1) | AU2016350701B2 (en) |
BR (1) | BR112018008865A8 (en) |
CA (1) | CA3001131A1 (en) |
CL (2) | CL2018001172A1 (en) |
CO (1) | CO2018004132A2 (en) |
CR (1) | CR20180306A (en) |
EA (1) | EA201891106A1 (en) |
EC (1) | ECSP18041501A (en) |
IL (1) | IL258725A (en) |
MA (1) | MA43163A (en) |
MX (1) | MX2018005517A (en) |
PE (1) | PE20181300A1 (en) |
PH (1) | PH12018500933A1 (en) |
SG (1) | SG11201803009VA (en) |
TW (1) | TW201722985A (en) |
WO (1) | WO2017079117A1 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
DK3283508T3 (en) | 2015-04-17 | 2021-05-31 | Alpine Immune Sciences Inc | Immunomodulatory Proteins with Tunable Affinities |
CA3003721C (en) | 2015-11-02 | 2024-02-06 | Blueprint Medicines Corporation | Inhibitors of ret to treat cancer |
JP6936221B2 (en) | 2015-11-02 | 2021-09-15 | ファイブ プライム セラピューティクス, インコーポレイテッド | CD80 extracellular domain polypeptides and their use in cancer treatment |
WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
AU2018235835A1 (en) | 2017-03-16 | 2019-09-05 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
AU2018235838B2 (en) | 2017-03-16 | 2023-12-14 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
CA3058477A1 (en) | 2017-04-11 | 2018-10-18 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
EP3628070B1 (en) | 2017-04-28 | 2021-09-08 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides for use in increasing central memory t cells |
WO2019040780A1 (en) | 2017-08-25 | 2019-02-28 | Five Prime Therapeutics Inc. | B7-h4 antibodies and methods of use thereof |
WO2019073080A1 (en) * | 2017-10-13 | 2019-04-18 | Ose Immunotherapeutics | Modified anti-sirpa antibodies and uses thereof |
AU2019228600A1 (en) | 2018-03-02 | 2020-09-24 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
SI3773589T1 (en) | 2018-04-03 | 2024-03-29 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
SG11202100642UA (en) * | 2018-08-29 | 2021-03-30 | Five Prime Therapeutics Inc | Cd80 extracellular domain fc fusion protein dosing regimens |
AU2019343850B2 (en) * | 2018-09-17 | 2024-06-06 | Gi Innovation, Inc. | Fusion protein comprising IL-2 protein and CD80 protein, and use thereof |
US20220177587A1 (en) * | 2018-09-19 | 2022-06-09 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
CN111423512B (en) * | 2019-01-10 | 2024-01-05 | 北京比洋生物技术有限公司 | Multi-targeting fusion protein for blocking vascular endothelial cell growth and activating T cells and pharmaceutical composition comprising same |
TW202045544A (en) | 2019-02-22 | 2020-12-16 | 美商戊瑞治療有限公司 | Cd80 extracellular domain fc fusion proteins for treating pd-l1 negative tumors |
US20220348657A1 (en) | 2019-04-18 | 2022-11-03 | Five Prime Therapeutics, Inc. | Bioassay for t-cell co-stimulatory proteins containing fc domains |
US11788072B2 (en) * | 2019-04-30 | 2023-10-17 | Innovative Cellular Therapeutics Holdings, Ltd. | Activation of APC in immunotherapy |
US20220227834A1 (en) | 2019-05-03 | 2022-07-21 | Five Prime Therapeutics, Inc. | Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins |
AU2020389422A1 (en) * | 2019-11-20 | 2022-06-02 | Gi Cell, Inc. | Medium composition for culturing T cells and method for culturing T cells using same |
JP7381750B2 (en) * | 2019-11-20 | 2023-11-15 | ジーアイ・セル・インコーポレイテッド | Composition for culturing natural killer cells and method for producing natural killer cells using the same |
WO2021101273A2 (en) * | 2019-11-20 | 2021-05-27 | 주식회사 지아이셀 | Composition for culturing regulatory t cells and use thereof |
CN110732021B (en) * | 2019-11-21 | 2020-08-25 | 北京启辰生生物科技有限公司 | Composition for relieving tumor immunosuppression and application thereof |
CN110743006B (en) * | 2019-11-22 | 2020-08-25 | 北京启辰生生物科技有限公司 | Composition for synergistically relieving immune cell failure and application |
MX2022006295A (en) * | 2019-11-27 | 2022-06-08 | Gi Cell Inc | Composition for anticancer treatment, comprising nk cells and fusion protein which comprises il-2 protein and cd80 protein. |
TW202146437A (en) * | 2020-02-26 | 2021-12-16 | 美商戊瑞治療有限公司 | Cd80 extracellular domain fc fusion protein therapy |
PE20231293A1 (en) | 2020-06-03 | 2023-08-22 | Boehringer Ingelheim Int | RECOMBINANT RHABDOVIRUS ENCODING A CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN |
KR102373965B1 (en) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Pharmaceutical composition for enhancing radiotherapy containing fusion protein comprising il-2 protein and cd80 protein |
WO2022226170A1 (en) * | 2021-04-22 | 2022-10-27 | Cornell University | The immunomodulatory ligand b7-1 mediates synaptic remodeling by p75ntr |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521288A (en) | 1990-03-26 | 1996-05-28 | Bristol-Myers Squibb Company | CD28IG fusion protein |
US7070776B1 (en) | 1990-03-26 | 2006-07-04 | Bristol-Myers Squibb Company | Methods for blocking binding of CD28 receptor to B7 |
US6071716A (en) | 1990-10-01 | 2000-06-06 | Dana-Farber Cancer Institute | DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells |
US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
US5858776A (en) | 1993-11-03 | 1999-01-12 | Repligen Corporation | Tumor cells with increased immunogenicity and uses therefor |
US6824779B1 (en) | 1993-07-26 | 2004-11-30 | Dana-Farber Cancer Institute, Inc. | Methods for inhibiting the interaction of B7-2 with its natural ligand |
US6130316A (en) | 1993-07-26 | 2000-10-10 | Dana Farber Cancer Institute | Fusion proteins of novel CTLA4/CD28 ligands and uses therefore |
US6218510B1 (en) | 1994-03-02 | 2001-04-17 | Brigham & Woman's Hospital | B7-1 and B7-2 polypeptides |
EP0749323B1 (en) | 1994-03-08 | 2000-11-29 | Dana-Farber Cancer Institute | Methods for modulating t cell anergy |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US20020147326A1 (en) | 1996-06-14 | 2002-10-10 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
US6491925B2 (en) | 1996-08-15 | 2002-12-10 | Emory University | Compositions and methods for cancer prophylaxis and/or treatment |
WO1998058965A2 (en) | 1997-06-20 | 1998-12-30 | Innogenetics N.V. | B7-binding molecules for treating immune diseases |
AU6366999A (en) | 1998-10-30 | 2000-05-22 | Takeda Chemical Industries Ltd. | Betacellulin protein-containing preparations |
US7011833B1 (en) | 1999-05-06 | 2006-03-14 | Genetics Institute, Inc. | Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent |
MXPA02001877A (en) | 1999-08-23 | 2002-08-20 | Dana Farber Cancer Inst Inc | Pd1, a receptor for b74, and uses therefor. |
US6429303B1 (en) | 1999-09-03 | 2002-08-06 | Curagen Corporation | Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same |
US7064111B1 (en) | 1999-10-05 | 2006-06-20 | Georgetown University | Use of soluble costimulatory factor for tumor immuno-gene therapy |
US7183376B2 (en) | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
WO2002078524A2 (en) | 2001-03-28 | 2002-10-10 | Zycos Inc. | Translational profiling |
AU2002368044A1 (en) | 2001-06-22 | 2004-04-19 | Maxygen, Inc. | Co-stimulatory molecules |
WO2003039486A2 (en) | 2001-11-09 | 2003-05-15 | Idec Pharmaceuticals Corporation | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
JP2006517191A (en) | 2002-12-30 | 2006-07-20 | アムジエン・インコーポレーテツド | Combination therapy using costimulatory factors |
SI1638941T1 (en) | 2003-05-22 | 2010-11-30 | Abbott Lab | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
WO2005016266A2 (en) | 2003-08-04 | 2005-02-24 | Bristol-Myers Squibb Company | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
EP1814568A4 (en) | 2004-10-29 | 2009-08-12 | Univ Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
DK2343320T3 (en) | 2005-03-25 | 2018-01-29 | Gitr Inc | ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF |
EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
DK2559690T3 (en) | 2005-05-10 | 2016-04-25 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of use thereof |
NZ565511A (en) * | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
EP1971583B1 (en) | 2005-12-20 | 2015-03-25 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US9868961B2 (en) | 2006-03-30 | 2018-01-16 | The Regents Of The University Of California | Methods and compositions for localized secretion of anti-CTLA-4 antibodies |
CL2007002650A1 (en) | 2006-09-19 | 2008-02-08 | Incyte Corp | COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS. |
WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008037080A1 (en) | 2006-09-29 | 2008-04-03 | Universite De Montreal | Methods and compositions for immune response modulation and uses thereof |
CA2682266A1 (en) | 2007-03-28 | 2008-10-09 | Biogen Idec Inc. | Treatment of hodgkins lymphoma |
US20100203010A1 (en) | 2007-03-28 | 2010-08-12 | Biogen Idec Inc. | Modulation of tumor microenvironment |
EP3357338A1 (en) | 2007-03-30 | 2018-08-08 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
AU2008266951B2 (en) | 2007-06-18 | 2013-12-12 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor PD-1 |
EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
CN101358225B (en) * | 2007-07-30 | 2012-02-01 | 厦门大学 | Method for preparing high sialic acid content immune globulin antibody and application |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
EP2612868B1 (en) * | 2007-11-01 | 2018-08-15 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
WO2009089149A1 (en) | 2008-01-03 | 2009-07-16 | The Johns Hopkins University | B7-h1 (cd274) antagonists induce apoptosis of tumor cells |
SI2250279T1 (en) | 2008-02-08 | 2016-10-28 | Medimmune, Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
RS54233B1 (en) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Compositions of pd-1 antagonists and methods of use |
LT3023438T (en) | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antibodies |
US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | Simultaneous inhibition of pd-l1/pd-l2 |
NZ602161A (en) | 2010-03-04 | 2014-12-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
RU2710717C2 (en) | 2010-09-09 | 2020-01-10 | Пфайзер Инк. | Molecules which bind to 4-1bb |
MX354359B (en) | 2011-03-29 | 2018-02-28 | Roche Glycart Ag | Antibody fc variants. |
NO2694640T3 (en) | 2011-04-15 | 2018-03-17 | ||
LT2699264T (en) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
HUE040455T2 (en) | 2011-06-30 | 2019-03-28 | Genzyme Corp | Inhibitors of t-cell activation |
WO2013014668A1 (en) | 2011-07-24 | 2013-01-31 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
TW201840336A (en) | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
US8956619B2 (en) | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
US9567642B2 (en) | 2012-02-02 | 2017-02-14 | Massachusetts Institute Of Technology | Methods and products related to targeted cancer therapy |
WO2013116656A1 (en) | 2012-02-03 | 2013-08-08 | Emory University | Immunostimulatory compositions, particles, and uses related thereto |
CN104470949A (en) | 2012-05-15 | 2015-03-25 | 百时美施贵宝公司 | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
UY34887A (en) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
US9790276B2 (en) * | 2012-12-18 | 2017-10-17 | The Rockefeller University | Glycan-modified anti-CD4 antibodies for HIV prevention and therapy |
JP6449229B2 (en) | 2013-03-15 | 2019-01-09 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | FC variant |
CA2905798C (en) | 2013-03-15 | 2023-01-24 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
WO2014144621A2 (en) | 2013-03-15 | 2014-09-18 | Pyranose Biotherapeutics, Inc. | Modified fc fusion proteins |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
TW201605896A (en) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | GITR antigen binding proteins |
EP3470081A1 (en) | 2013-10-01 | 2019-04-17 | Mayo Foundation for Medical Education and Research | Methods for treating cancer in patients with elevated levels of bim |
EP3087099A4 (en) | 2013-12-23 | 2017-07-19 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
TWI693232B (en) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof |
WO2016007235A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
WO2016044189A1 (en) | 2014-09-15 | 2016-03-24 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists |
IL254335B2 (en) | 2015-03-16 | 2023-04-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Isolated peptides derived from the b7 ligand dimer interface and uses thereof |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
DK3283508T3 (en) | 2015-04-17 | 2021-05-31 | Alpine Immune Sciences Inc | Immunomodulatory Proteins with Tunable Affinities |
IL284375B (en) | 2015-04-30 | 2022-07-01 | Psioxus Therapeutics Ltd | Replication competent oncolytic group b adenovirus |
IL297090A (en) | 2015-07-30 | 2022-12-01 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
CN106397592A (en) | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | Single-domain antibody directed at programmed death ligand (PD-L1) and derived protein thereof |
WO2017042814A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Use of perforin positive immature dendritic cells in disease treatment |
JP2018534245A (en) | 2015-09-14 | 2018-11-22 | アルパイン イミューン サイエンシズ インコーポレイテッド | Tunable variant immunoglobulin superfamily domains and modified cell therapy |
JP6936221B2 (en) | 2015-11-02 | 2021-09-15 | ファイブ プライム セラピューティクス, インコーポレイテッド | CD80 extracellular domain polypeptides and their use in cancer treatment |
BR112018012180A2 (en) | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | virus encoding an anti-tcr antibody or fragment |
CN108884164B (en) | 2016-02-25 | 2022-12-27 | 细胞医学瑞士公司 | Modified cells for immunotherapy |
CN109311945A (en) | 2016-03-02 | 2019-02-05 | Cue生物制药公司 | T cell modulability multimeric polypeptide and its application method |
HRP20240052T1 (en) | 2016-03-04 | 2024-03-29 | Io Biotech Aps | Combination therapy against cancer |
WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
BR112018073606A2 (en) | 2016-05-18 | 2019-02-26 | Cue Biopharma, Inc. | T-cell modulating multimeric polypeptides and methods of using them |
CA3024509A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
CA3038526A1 (en) | 2016-09-27 | 2018-04-05 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
EP3872180A1 (en) | 2016-10-20 | 2021-09-01 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
EP3628070B1 (en) | 2017-04-28 | 2021-09-08 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides for use in increasing central memory t cells |
SG11202100642UA (en) | 2018-08-29 | 2021-03-30 | Five Prime Therapeutics Inc | Cd80 extracellular domain fc fusion protein dosing regimens |
TW202045544A (en) | 2019-02-22 | 2020-12-16 | 美商戊瑞治療有限公司 | Cd80 extracellular domain fc fusion proteins for treating pd-l1 negative tumors |
US20220227834A1 (en) | 2019-05-03 | 2022-07-21 | Five Prime Therapeutics, Inc. | Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins |
-
2016
- 2016-11-01 JP JP2018520115A patent/JP6936221B2/en active Active
- 2016-11-01 EA EA201891106A patent/EA201891106A1/en unknown
- 2016-11-01 WO PCT/US2016/059838 patent/WO2017079117A1/en active Application Filing
- 2016-11-01 CR CR20180306A patent/CR20180306A/en unknown
- 2016-11-01 AU AU2016350701A patent/AU2016350701B2/en not_active Ceased
- 2016-11-01 MA MA043163A patent/MA43163A/en unknown
- 2016-11-01 TW TW105135388A patent/TW201722985A/en unknown
- 2016-11-01 SG SG11201803009VA patent/SG11201803009VA/en unknown
- 2016-11-01 PE PE2018000712A patent/PE20181300A1/en unknown
- 2016-11-01 BR BR112018008865A patent/BR112018008865A8/en not_active IP Right Cessation
- 2016-11-01 EP EP16794878.5A patent/EP3371208A1/en active Pending
- 2016-11-01 CN CN201680065219.7A patent/CN108884139A/en active Pending
- 2016-11-01 MX MX2018005517A patent/MX2018005517A/en unknown
- 2016-11-01 US US15/340,238 patent/US10273281B2/en active Active
- 2016-11-01 KR KR1020187014561A patent/KR20180069903A/en unknown
- 2016-11-01 CA CA3001131A patent/CA3001131A1/en not_active Abandoned
-
2018
- 2018-04-16 IL IL258725A patent/IL258725A/en unknown
- 2018-04-18 CO CONC2018/0004132A patent/CO2018004132A2/en unknown
- 2018-05-02 PH PH12018500933A patent/PH12018500933A1/en unknown
- 2018-05-02 CL CL2018001172A patent/CL2018001172A1/en unknown
- 2018-06-01 EC ECIEPI201841501A patent/ECSP18041501A/en unknown
-
2019
- 2019-03-07 US US16/295,978 patent/US20190194288A1/en not_active Abandoned
- 2019-03-15 US US16/354,689 patent/US11098103B2/en active Active
-
2020
- 2020-12-28 CL CL2020003392A patent/CL2020003392A1/en unknown
-
2022
- 2022-05-11 US US17/742,189 patent/US20240041979A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11098103B2 (en) | 2021-08-24 |
US20170145071A1 (en) | 2017-05-25 |
BR112018008865A2 (en) | 2018-11-06 |
US10273281B2 (en) | 2019-04-30 |
BR112018008865A8 (en) | 2019-02-26 |
ECSP18041501A (en) | 2018-06-30 |
SG11201803009VA (en) | 2018-05-30 |
US20190194288A1 (en) | 2019-06-27 |
PH12018500933A1 (en) | 2018-11-19 |
CO2018004132A2 (en) | 2018-11-30 |
MA43163A (en) | 2018-09-12 |
IL258725A (en) | 2018-06-28 |
AU2016350701B2 (en) | 2021-08-19 |
KR20180069903A (en) | 2018-06-25 |
JP2018535204A (en) | 2018-11-29 |
CL2020003392A1 (en) | 2021-07-19 |
CN108884139A (en) | 2018-11-23 |
CA3001131A1 (en) | 2017-05-11 |
WO2017079117A1 (en) | 2017-05-11 |
AU2016350701A1 (en) | 2018-05-31 |
EP3371208A1 (en) | 2018-09-12 |
CR20180306A (en) | 2018-10-16 |
US20190202889A1 (en) | 2019-07-04 |
JP6936221B2 (en) | 2021-09-15 |
TW201722985A (en) | 2017-07-01 |
MX2018005517A (en) | 2018-11-09 |
EA201891106A1 (en) | 2018-12-28 |
PE20181300A1 (en) | 2018-08-09 |
US20240041979A1 (en) | 2024-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018001172A1 (en) | CD80 extracellular domain polypeptides and their use in cancer treatment | |
CR20150664A (en) | MODULATORS OF ESTROGEN RECEIVERS AND THEIR USES | |
CL2015003271A1 (en) | Ester derivatives of androgen receptor modulators and methods for their use. | |
CL2016000807A1 (en) | Amino heteroaryl benzamides as kinase inhibitors. | |
CL2016003056A1 (en) | Sting modulating cyclic dinucleotides; Composition and pharmaceutical combination that includes them and their use for the treatment of diseases such as inflammation, allergic and autoimmune diseases, infectious diseases and cancer. | |
CL2016001364A1 (en) | Ror gamma modulators (rory) | |
MX2015011132A (en) | Polycyclic estrogen receptor modulators and uses thereof. | |
DOP2016000150A (en) | NEW INDAZOLCARBOXAMIDS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES | |
CR20150186A (en) | TRICYCLIC DERIVATIVES OF QUINOLINAS AND QUINOXALINAS | |
CL2016002027A1 (en) | Cyclopropylamine as an inhibitor of lsd1 | |
CL2016000298A1 (en) | Compounds derived from thieno [2,3-c] pyran with modulating activity of the cystic fibrosis transmembrane conductance regulator (cftr); pharmaceutical composition that includes them; Useful in the treatment of cystic fibrosis. | |
CL2016000153A1 (en) | Glioxamide substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis b | |
CL2016001609A1 (en) | Pharmaceutical compositions comprising azd9291. | |
CL2015003280A1 (en) | Benzimidazole derivatives as bromodomain inhibitors | |
UY36311A (en) | INDAZOLS REPLACED WITH BENCILO | |
CL2015002125A1 (en) | Modulators of nmda receptors of spiro-lactam and their uses. | |
UY36068A (en) | TGF-ß INHIBITORS AND METHODS OF USE | |
BR112012020558A2 (en) | androgen receptor modulators and their uses | |
UY36075A (en) | TUBULISINE DERIVATIVES | |
CL2016001840A1 (en) | Compounds derived from fused pyrimidines as inhibitors of the p97 complex; Pharmaceutical composition and use in cancer treatment. | |
MX2019012849A (en) | Methods of treatment with cd80 extracellular domain polypeptides. | |
CL2015000976A1 (en) | Compounds of 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine for use in the treatment of diabetes and its associated disorders. | |
CL2019001329A1 (en) | Pharmaceutical compositions modulating the 7-receptor of 5-hydroxytrritpine and methods of use. | |
BR112017009792A2 (en) | anti-pdgf-b antibodies and methods of use | |
DOP2017000058A (en) | TETRAHYDROQUINOLINE DERIVATIVES AS BROMODOMINUM INHIBITORS |